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Abstract
Background: Most of the many mutations described in human protein kinases are tolerated without significant
disruption of the corresponding structures or molecular functions, while some of them have been associated to a
variety of human diseases, including cancer. In the last decade, a plethora of computational methods to predict
the effect of missense single-nucleotide variants (SNVs) have been developed. Still, current high-throughput
sequencing efforts and the concomitant need for massive interpretation of protein sequence variants will demand
for more efficient and/or accurate computational methods in the forthcoming years.
Results: We present KinMut, a support vector machine (SVM) approach, to identify pathogenic mutations in the
protein kinase superfamily. KinMut relays on a combination of sequence-derived features that describe mutations
at different levels: (1) Gene level: membership to a specific group in Kinbase and the annotation with GO terms; (2)
Domain level: annotated PFAM domains; and (3) Residue level: physicochemical features of amino acids, specificity
determining positions, and functional annotations from SwissProt and FireDB. The system has been trained with
the set of 3492 human kinase mutations in UniProt for which experimental validation of their pathogenic or
neutral character exists. In addition, we discuss the relative importance of these independent properties and their
combination for the development of a kinase-specific predictor. Finally, we compare KinMut with other state-of-
the-art prediction methods.
Conclusions: Family-specific features appear among the most discriminative information sources, which allow us to
produce accurate results in a reliable and very simple way with minimal supervision. Our study aims to broaden the
knowledge on the mechanisms by which mutations in the human kinome contribute to disease with a particular
focus in cancer. The classifier as well as further documentation is available at http://kinmut.bioinfo.cnio.es/.
Background
Current high-throughput resequencing screenings [1-3]
represent a powerful set of techniques to discover large
numbers of mutations. Of these, only a small fraction are
causally implicated in disease onset and therefore, separat-
ing the wheat from the chaff is still a major challenge [4].
For a small subset of the new mutations discovered,
experimental information is available regarding the rela-
tionship between the mutation and disease, and for an
even smaller number of cases the underlying biochemical
mechanism is known. However, there is no information
for the remaining mutations. The requirement of a lot of
resources implies that it is not feasible to experimentally
test the association of all these mutations to disease, and
to characterize their functional effects. Nevertheless, this
problem is very amenable to in silico predictors [4-6]. Dif-
ferent approaches are currently available to predict the
probability of a newly discovered mutation being impli-
cated in disease. Some methods make use of several fea-
tures to highlight crucial positions in a given protein, and
hence, rules are derived to predict the pathogenicity of
mutations. Another group of methods assumes that evolu-
tionarily conserved protein residues are important for pro-
tein structure, folding and function, whereby mutations in
these residues are considered deleterious [7]. Variations
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mutations by evaluating changes in evolutionarily con-
served PFAM motifs [8]. Moreover, a number of systems
use protein structures to characterize substitutions that
significantly destabilize the folded state. There are also
methods that integrate prior knowledge in the form of
both sequence-based and structure-based features from a
set of mutations (previously characterized as pathogenic
or neutral) to train an automatic machine learning system.
After this training process, the system can infer the patho-
genicity of new mutations based on the knowledge
acquired. These approaches, albeit similar in purpose,
implement very different machine-learning methods.
Among them, probably the most popular ones are: rule-
based systems [9-11], decision trees [12], random forests
[13,14], neural networks [15,16], Bayesian methods [17]
and SVMs [18-21]. Recently, some meta approaches have
been implemented, for instance, Condel [22] integrates
five of the most widely employed computational tools for
sorting missense single nucleotide variations.
Moreover, diverse datasets of mutations have been
employed for benchmarking the performance of different
methods, and depending on the scope of the predictor dif-
ferences exist, as well. Most of the predictors are generally
applicable to amino acid sequences from any protein
family, while a few of them include properties that apply
only to a given protein family of interest; i.e. protein
kinase-specific predictors [19]. These family-related fea-
tures bring discriminative information that justifies the
development of specialized predictors.
A broad number of mutations in the protein kinase
superfamily have been reported in the literature [23] and a
subset of them is known to disrupt protein structure and
function [24]. For some cases, since human protein kinases
are involved in a plethora of physiological functions, this
disruption can be causally associated to disease [25]. Still,
the majority of protein kinase mutations are tolerated with-
out apparent significant effects [26,27]. In previous publica-
tions, we have discussed the preferential distribution of
germline pathogenic deviations [28] and driver somatic
mutations [29] to regions of functional and structural
importance. Here, we present the basis for the develop-
ment of a computational method to predict the impact of
mutations on the function of protein kinases - KinMut -
based on these features.
In the work presented here, we explored the signifi-
cance of disease-associated mutations in terms of
sequence-derived characteristics at different levels:
1. At the gene level: membership to a KinBase group
[30] and Gene Ontology [31] terms.
2. At the domain level: the occurrence of the mutation
inside a PFAM [32] domain.
3. At the residue level: several properties including
amino acid types, functional annotations from SwissProt
[33] and FireDB [34], and specificity-determining posi-
tions (SDPs) [35].
Accordingly, we analyzed the independent significance
of these properties and their combination with a support
vector machine (SVM) and we discussed the benefits and
pitfalls of using the information available for the develop-
ment of a family-specific predictor. Finally, we compared
KinMut with regard to other state-of-the-art prediction
methods.
Results
Construction of the disease and neutral datasets
The method was trained and evaluated using a dataset
derived from UniProt [33], which has been benchmarked
previously for a number of classifiers with satisfactory
results [36]. After our filtering pipeline, 865 mutations in
65 human kinases formed the ‘disease dataset’, whereas
the ‘neutral dataset’ consisted of 2,627 mutations in 447
human kinases. For classification purposes, each mutation
is described by 142 sequence-features. Full details in
Methods.
Optimization of the prediction method
To classify the mutations in the human kinome as disease-
associated or neutral according to the sequence features of
the mutations, we used a Support Vector Machine (SVM).
This type of approach has previously been widely used to
automatically prioritize disease-associated mutations
[18,19,21,37,38] and it has been demonstrated to outper-
form other approaches such as Bayesian classifiers and
neural networks [19].
Our implementation of the SVM relied on a radial basis
function (rbf) kernel. Two parameters are crucial for the
performance of the classifier, the soft-margin penalty (C)
and the radius (g): C represents the amount of errors
allowed during the training and evaluation steps, while g
represents the width of the SVM radial function. These
parameters can be optimized to improve the predictions.
Hence, we conducted a grid search in a wide range of
values for these parameters, to decide which pair predicts
with the best performance, using the f-score as optimiza-
tion function (a more detailed description of the optimiza-
tion can be found in the Methods section). The optimal
values used during the analyses corresponded to C =8
and g =6·1 0
-4 (Additional file 1). Comparable results
were obtained when the under the ROC curve (AUC) was
tested as selection criteria (Additional file 2).
Evaluation of the performance of the classifier
We avoided over-fitting the classifier by applying a 10-fold
cross-validation approach where 8 random sets were used
during the training step, one for the validation phase and
one for the evaluation. This process was repeated 90 times
to allow all possible combinations of sets to be used during
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zation of the kernel relies on the f-score, the performance
of the classifier is assessed by several additional measures,
such as accuracy, precision, recall and the Matthew’s cor-
relation coefficient (MCC).
On average, the classifier predicted the pathogenicity of
kinase mutations robustly (AUC=0.81). However, different
threshold values could modulate the output of the classi-
fier, as summarized in Table 1, and selecting an appropri-
ate threshold is a critical step in developing a classifier.
Relaxed thresholds, such as –0.75, enable the detection of
more disease-associated mutations (increased recall), albeit
at the cost of a larger number of false positives (reduced
precision). Conversely, higher thresholds of conservative
classifiers, such as –0.5, reduce the frequency of a muta-
tion being classified as pathogenic, consequently predict-
ing a smaller set of more reliable disease-associated
mutations. We chose the threshold of –0.5 whereby the
f-score (66.7%) is maximal. Using this conservative thresh-
old, the classifier predicted 83.3% of the mutations cor-
rectly. Regarding the pathogenic dataset, 75.2% of the
observed mutations were recovered on average across all
k-folds with a precision of 60%. The average MCC was 0.6.
Evaluation of the dependence of the performance on the
abundance of information
When the different groups in which the protein kinase
superfamily is divided were superimposed, we observed
differences in the number of mutations that populated the
groups (Table 2). These differences are consistent with the
phylogenetic distribution of the literature-extracted muta-
tions we observed earlier [23]. A small number of these
groups contain most of the mutations, while others lack or
contain very few disease-associated mutations. For the
mutations in these less populated groups, only group
membership suffices to consider them as neutral and this
neutrality is likely an artifact due to the lack of experi-
ments assessing the pathogenicity of the mutations.
Consequently, we evaluated the dependence of the
results on the amount of disease-associated mutations
available. A second dataset was generated with only the
highly populated groups: TK, TKL, Atypical_PI3-PI4,
CAMK, RGC, CMGC, AGC and Atypical_ADCK. Under
this constraint the ‘disease dataset’ consisted of 814
mutations in 54 human kinases, while the neutral dataset
contained 1,775 in 297 proteins.
When only the groups sufficiently populated with dis-
ease-associated mutations were considered, on average we
correctly predicted 76.8% of the remaining mutations
across all k-folds, with the optimized values of C = 8 and
g =1 0
–4 (Additional file 3). With respect to the pathogenic
dataset, we recovered 73.3% of the disease-associated muta-
tions with a precision of 64.7% (MCC: 0.5, Table 3), com-
parable to that obtained when all the mutations from all
the kinase groups were considered, thereby confirming that
the bias in the data does not significantly affect the results.
However, clear differences were observed when the
groups were compared individually (Table 4). For the
groups with a reasonable number of mutations, the per-
formance of the classifier was considerably better than
with the less populated groups. This was especially clear
for the precision of the predictions, which was consis-
tent with the fact that the use of a sufficient number of
support vectors helps the classifier learn how to discern
disease-associated mutations properly.
Table 1 Performance of the classifier depending on the SVM classification thresholds applied using all kinase groups
SVM threshold Accuracy (%) Precision (%) Recall (%) F-score MCC
-1.00 74.3 46.5 89.1 61.1 0.6
-0.75 80.9 56.1 79.8 65.9 0.6
-0.5 83.3 60.0 75.2 66.7 0.6
-0.25 80.6 60.0 66.1 62.9 0.5
0.00 82.3 58.6 47.2 52.3 0.4
Performance of the classifier depending on the SVM classification thresholds applied using all kinase groups.
Table 2 Number of mutations in each of the groups in
which UniProt divides the protein kinase superfamily
Group Disease Neutral Total
TK † 496 565 1061
TKL † 172 151 323
Atypical_PI3-PI4 † 49 138 187
CAMK † 40 518 558
Other 36 411 447
RGC † 23 35 58
CMGC † 18 178 196
AGC † 16 190 206
STE 7 222 229
Atypical_ADCK 6 14 20
Atypical_Alpha-type 1 88 89
CK1 1 52 53
NEK 0 45 45
Atypical_RIO 0 14 14
Atypical_PDK-BCKDK 0 5 5
Atypical_FAST 0 1 1
Number of mutations in each of the groups in which UniProt divides the
protein kinase superfamily. The groups enriched in disease-associated
mutations are highlighted by †.
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To evaluate the contribution of each individual feature to
the classification, the features were ranked according to
t h ev a r i a t i o ni nt h em o d u l eo ft h ew e i g h tv e c t o ro ft h e
trained SVM (║ω║
2)w h e ne a c hf e a t u r ew a sr e m o v e df r o m
the set of support vectors. The feature whose removal
minimized the variation in module was considered to con-
tribute the least to the hyperplane that separates the two
classes of examples (pathogenic/neutral) with a maximum
margin. This ranking is shown in Additional file 4 (Supple-
mentary Table 1). The ranking derived from the SVMs has
been applied for variable selection in many classification
problems [39,40]. According to the SVM-based criteria,
the top ranked features are only based on the subset of
support vectors that are ‘borderline’ cases.
Gene Ontology (GO) functional annotations contribu-
ted the most to the classification. This feature is
encoded as the sum of GO terms log-odds ratio,
sumGOLOR, to be able to compare between the dis-
ease-associated and neutral datasets and corresponds to
a classification at the gene-level; it represents the pro-
portion of disease-associated and neutral kinase genes
that are annotated with a particular GO term, and it
can be used to identify the GO terms characteristic of
neutral or disease-prone genes. If the individual terms
from the biological process sub-ontology are analyzed,
interesting trends can be observed. For example, the
most pathogenic biological processes are enriched in
terms associated with protein localization, cell prolifera-
tion and tissue development, all aspects related to dis-
ease and particularly cancers. Pathogenic and neutral
genes are differentially enriched in terms from the
molecular function sub-ontology. While neutral genes
are associated with basic kinase activity functions, dis-
ease-associated genes are enriched in terms associated
with hormone binding, co-factors and interaction part-
ners. The most representative GO terms for each of the
classes are shown in Supplementary Table 2 for neutral
genes and Supplementary Table 3 for disease-associated
ones (Additional file 4).
The next group of features in the order of relevance for
the predictor is linked to the positions that confer specifi-
city at the family level (i.e., the tree-determinants). The
calculation of this score is based on our in-house imple-
mentation of the S3Det method [35]. However, the current
implementation of the method did not provide a continu-
ous measure of tree-determinant characteristics and thus,
we implemented this additional possibility. The coinci-
dence of a given residue with the alignment of the rest of
t h ef a m i l ym e m b e r s ,a n dt h ed i f f e r e n c e sr e g a r d i n gt h e
sequences outside the subfamily, were measured with an
f-score as described in the Methods. Three different scores
were calculated: the f-score for the wild type amino acid;
the f-score for the mutant residue; and the difference
between these two scores as a measure of the relevance of
the change introduced.
Following these two important features of the predictor
is the Kyte-Doolittle hydrophobicity change, the presence
of a PFAM domain (in particular the tyrosine kinase
domain), the functional annotation of the residues in Swis-
sProt [33] and PhosphoELM [41], and the evolutionary
SIFT score [7] or the amino acid types involved in the
change.
Interestingly, among the genome-wide features, some
kinase-specific features also emerged as being relevant.
For instance, to reinforce the important role of gene-
level characterization, classifying kinases into the differ-
ent groups in KinBase [30] was an important feature
(particularly TK, CAMK, CK1 and TKL among the
canonical protein kinases, and Alpha-type, ADCK or
PI3-PI3 among the atypical ones), as observed previously
[19].
Table 3 Performance of the classifier depending on the
SVM classification thresholds applied when using groups
highly populated in disease mutations only
SVM threshold Accuracy (%) Precision (%) Recall (%) MCC
-1.000 71.5 51.4 88.9 0.6
-0.750 77.0 61.7 81.5 0.6
-0.500 76.8 64.7 73.3 0.5
-0.250 79.4 68.1 69.9 0.5
0.000 71.6 60.7 56.3 0.4
Performance of the classifier depending on the SVM classification thresholds
applied when using groups highly populated in disease mutations only.
Table 4 Performance of the classifier when the groups in
which UniProt divides the protein kinase superfamily are
considered individually
Group Accuracy (%) Precision (%) Recall (%) MCC
CMGC † 91.5 87.5 8.6 0.1
TKL † 68.7 70.5 70.9 0.4
TK † 71.3 69.7 68.3 0.4
RGC † 58.2 47.9 61.3 0.2
Atypical_PI3-PI4 † 70.6 47.1 100 0.8
STE 96.8 43.7 11.1 0.1
AGC † 90.8 43.3 61.1 0.5
Other 88.9 41.6 95.4 0.9
CK1 97.7 33.3 22.2 0.2
Atypical_Alpha-type 89.9 9.1 88.9 0.8
CAMK † 55.5 8.3 51.9 0.1
Atypical_ADCK 70.0 0 0 0
NEK 100 0 0 0
Atypical_RIO 100 0 0 0
Atypical_PDK-BCKDK 100 0 0 0
Atypical_FAST 100 0 0 0
Performance of the classifier when the groups in which UniProt divides the
protein kinase superfamily are considered individually. Groups enriched in
disease-associated mutations are indicated by †.
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To test the performance of our classifiers, we compared
our results with those of five well-established predictors
of pathogenicity: SIFT [7], MutationAssessor [9], SNAP
[16], SNPs&GO [18] and a kinase-specific method [19].
This set of classifiers represents a wide variety of
approaches and scopes: genome-wide and kinase-specific
classifiers, different classification approaches (rule-based,
neural networks, linear SVMs and radial basis SVMs)
and a broad set of classification features. The results of
this benchmark are shown in Table 5.
Four genome-wide classifiers SNPs&GO, MutationAs-
sessor, SIFT and SNAP were evaluated with the same
kinase dataset as that used to train and evaluate KinMut
(Additional file 5). Predictions from SNP&GO and
MutationAssessor were obtained through their respec-
tive online servers while SIFT and SNAP predictions
were retrieved from SNPdbe [42]. Interestingly, when
these methods were evaluated with the protein kinase
dataset, performance dropped significantly compared to
those reported in the original publications for a wider
range of protein families (Table 5). It is worth noting
that this decrease in the overall performance demon-
strates that the protein kinases u p e r f a m i l yi sac h a l l e n -
ging scenario, justifying the need for kinase-specific
classifiers at the cost of scope.
Our predictor generated results with the kinase dataset
comparable to those obtained by the best predictor,
SNPs&GO. In addition, KinMut performed better than
MutationAssessor, SIFT and SNAP (Table 5). Our
method yields better results than the kinase-specific
method proposed by Torkamani and co-workers, the
only method against which a direct comparison can be
made. Unfortunately, the original publication did not
provide information about recall, precision and the
pathogenic mutations resulting from their method.
Hence, this method was only compared for accuracy and
MCC. Our results are more accurate as we correctly
predicted 83.3% of the cases compared to the 77% pre-
dicted by the other method. In addition, the correlation
coefficient was slightly better in our case, 0.6 compared
to 0.5. These results indicate that our choice of features
concentrated more predictive power.
Implementation of the predictor as a web server
We implemented our pipeline to predict mutation patho-
genicity in the protein kinase superfamily as a web server,
KinMut, which is publicly available at http://kinmut.
bioinfo.cnio.es. The server displays the mutations, a sum-
mary of the analyzed features and the SVM score for
each prediction. Mutations with an SVM score greater
than –0.5 are considered damaging, according to the
threshold discussed above.
Discussion
Performance of the classifier and the benefits of family-
specific prediction
It is definitely not easy to compare the capabilities of dif-
ferent prediction methods and many technical difficulties
arise [6]. Choosing an objective testing dataset is the
most difficult, especially when the datasets used in the
original publications are not equivalent. Moreover,
increased predictive capabilities would be expected if the
testing dataset had already been presented to the classi-
fier during the learning process. This is very likely the
case for the kinase dataset, which is a strict subset of the
most commonly used training dataset [36]. Consequently,
the results presented represent a means to understand
the capabilities of KinMut in its context rather than a
detailed ranking of prediction methods.
KinMut achieves a level of performance similar to that
obtained by the best predictors, SNPs&GO [18] and it out-
performs other reference methods such as SIFT [7], SNAP
[16] and MutationAssessor [9] when evaluated within the
framework of the kinase dataset. It also achieves better
results than Torkamani’s kinase-specific [19] method.
Table 5 Summary of the performance of other state-of-the-art classifiers of mutations, either general or kinase-specific
Method Scope Accuracy (%) Precision (%) Recall (%) MCC
KinMut Kinase† 83.3 60.0 75.2 0.6
SNPs&GO [18] Kinase† 82.3 62.8 77.5 0.6
Torkamani [19] Kinase 77.0 - - 0.5
MutationAssessor [9] Kinase† 53.8 41.6 95.6 0.5
SNAP [16] Kinase† 49.4 34.0 93.1 0.4
SIFT [7] Kinase† 77.6 37.8 27.9 0.2
SNPs&GO [18] Genome-wide 82.0 83.0 78.0 0.6
MutationAssessor [9] Genome-wide 79.0 - - -
SNAP [16] Genome-wide 78.2 76.7 80.2 -
SIFT [7] Genome-wide 68.3 66.1 56.5 0.3
Summary of the performance of other state-of-the-art classifiers of mutations, either general or kinase-specific. Performance was measured in terms of overall
accuracy recall and the Matthews correlation coefficient. General methods with which the prediction corresponds to our dataset are marked with †. The
remaining results for the classifiers displayed here were taken directly from their original publications
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best classifier, SNPs&GO, whose capability we probably
overestimated since it has been trained with all the muta-
tions in UniProt, which are very likely included in the
subset of kinase mutations, what gives SNPs&GO some
advantage since the classifier had already been presented
with the mutations. Thus, given that it is not possible to
train the predictor without the kinase mutations, we
assume this artifactual increase in performance to be
acceptable for the analysis presented here.
Probably, the similarity in the performance is given by
the use of GO terms since both methods - even though
they differ in their scope and implementation - benefit
from functional information encoded as GO terms at the
gene level, which is the most discriminative feature of our
classifier.
Our predictor performs beyond the capabilities of the
only method against which an utterly fair comparison can
be conducted, Torkamani’s kinase-specific predictor [43],
at least in terms of accuracy and correlation. Unfortunately,
the authors of this method did not provide information
about its recall, precision and output, to enable a better
comparison to have been made. Interestingly, Torkamani’s
and our classifiers share several properties: amino acid
types; kinase group membership, which the authors state
to be critical for classification; biochemical properties such
as the Kyte-Doolittle hydrophobicity index; and evolution-
ary conservation. In spite of these similarities, Torkamani’s
method does not benefit from intra-family specificity posi-
tions or from GO annotations, which we have shown to be
crucial for prediction (see above). This might have caused
the differences in performance observed.
Moreover, it is not surprising that KinMut predicts
more accurately than SIFT, being the latter used as a
classification feature. The difference in performance
should be attributed to the predictive power of the addi-
tional features and the machine-learning approach.
Current genome-wide predictors of mutation pathogeni-
city perform well on average, probably because they can
use the huge amount of mutation data available. However,
most of these predictors only exploit the subset of features
that could be generalized to the entire range of protein
families in the human proteome, which constitutes an
intrinsic limitation. By contrast, family-specific predictors,
such as the method presented here for the protein kinase
superfamily, can overcome this limitation and benefit from
features that apply only to the protein family of interest.
These family-specific features might capture aspects of
pathogenicity that are unique to that given protein family.
We explored the basis of using kinase-specific features,
such as kinase group membership, annotation with certain
GO terms and the presence of determined PFAM domains,
which are relevant for predicting pathogenicity in the pro-
tein kinase superfamily. Accordingly, the performance of
genome-wide methods decreases when they are confronted
with the set of kinase mutations.
Indeed, the family-specific nature of our method allowed
us to explore features that are unique to the protein kinase
superfamily, retaining valuable information on mutation
pathogenicity. In our case, membership to a particular
kinase group and the occurrence of mutations in the cata-
lytic protein kinase domain were important features that
are unique to the protein kinase superfamily. This is in full
agreement with previous observations that reached similar
conclusions [19,43].
The results provided here reinforce the idea that for
well-studied families like the kinase superfamily, family-
specific classifiers can use unique features that are only
valid in the context of this specific superfamily, thereby
improving performance over general purpose methods.
Regarding the dissimilarities between the different
branches of the kinase phylogenetic tree, we demonstrated
that more accurate results were obtained for groups with
sufficient data that allowed the classifier to learn to weight
the importance of the individual contribution of the fea-
tures precisely. Moreover, this group membership was one
of the most triggering features of our classification. There
are groups in which very few (or even no) pathogenic
mutations have been described and as such, in these cases
group membership is a powerful means to predict neutral
mutations. However, since the mutational landscape is far
from complete, we cannot discern whether this is a reli-
able scenario (where these kinase groups do not elicit
pathogenicity) or rather an artifact due to a gap in our cur-
rent knowledge that will be filled when new mutations are
discovered. Indeed, the uneven, heterogenic, distribution
of experimental evidence regarding the different kinase
groups does not only affect the number of mutations dis-
covered but also, the quality and thoroughness of features
such as GO or UniProt annotations, which is very likely to
influence the predictive capacity of our system. We expect
that, in the near future, ongoing genomic projects will
help us understand the links between mutations in all the
kinase groups and disease, thereby boosting the capability
of kinase-specific prediction methods beyond the limits of
current highly populated groups.
The current practical use of our method is as a com-
ponent of a system that ranks mutations by their poten-
tial importance in the context of cancer genome analysis
in a preclinical environment.
Methods
Mutation dataset
The mutation data used here was derived directly from
UniProt [33] (release 2011_01; Jan 11, 2011) after apply-
ing the following constraints:
1. The protein is annotated as a protein kinase in
UniProt.
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3. The mutation corresponds to non-synonymous,
non-truncating single point coding mutations. Other
mutation types such as insertions, deletions, copy num-
ber alterations, truncating and silent mutations were not
considered in this analysis.
The use of a UniProt derived dataset has recently been
benchmarked for a number of classifiers with satisfac-
tory results [36].
Following this pre-filtering step, we classified the
mutations as disease or neutral mutations according to
the annotation in UniProt. There is a third group in
UniProt that aggregates the mutations for which insuffi-
cient information is available, mutations that were ruled
out of this analysis. After the whole selection process,
the ‘disease dataset’ that includes mutations for which
there is experimental evidence of their disease associa-
tion, contained 865 mutations in 65 human kinases
(Additional file 6). By contrast, the ‘neutral dataset’ that
contains mutations with no experimental proof of asso-
ciation to disease, contained 2,627 mutations in 447
human protein kinases (Additional file 7). For classifica-
tion purposes, 142 sequence features describe each
mutation.
Implementation and optimization of the classifier
To implement the Support Vector Machine classifier we
used the SVMLight (http://www.cs.Cornell.edu/people/
tj/svm_light/) package with a radial basic function (RBF)
kernel:
K(xi, xj)=exp(–G║xi – xj║
2))
In this manner, two parameters are crucial to the per-
formance of the classifier: the soft-margin penalty (C)
and the radius (g). These parameters were optimized
using a grid search where an exhaustive evaluation was
carried out for values ranging between 0 ≤ C ≤ 8i n1
unit steps, and 10
–4 ≤ g ≤ 10
–2 increasing by 5 · 10
–4 after
each run. We used the f-score as optimization criteria. In
order to ensure fairness, we conducted a k-fold cross-
validation analysis for each of the C-gamma tuples. We
randomly distributed the mutations in 10 different sub-
sets: 8 sets were used for training, one set for validation
and 1 set for evaluation of the performance. We forced
each of the subsets as evaluation set (which was kept
apart at this stage), and we rotated the other 9 so that
each of them could be used as validation set while the
remaining 8 constitute the training set. Each independent
run provides a partial f-score, and the mean across the 90
partial f-scores provides the average f-score of that given
C-gamma tuple that was used as selection criteria. This
approach ensures that the f-score is maximized and there
are no biases in the selection of the datasets, while we
avoid over-fitting by evaluating the classifier with
mutations that had already been presented to it during
the training process.
Evaluation of performance
The performance of our classifier was evaluated using a
10-fold cross-validation approach as described above.
The process is repeated 90 times to ensure that all sub-
sets of mutations are used for each purpose. The classi-
fier’s performance is averaged across all combinations in
order to avoid over-interpreting the quality of the
method. The efficiency of the classifier can be assessed
in many ways and here we describe the most illustrative
ones.
Hereafter, we will refer to the following abbreviations:
TP True positives, correctly predicted disease-asso-
ciated mutations.
FP False positives, neutral mutations predicted as dis-
ease prone.
TN True negatives, correctly predicted neutral
mutations.
FN False negatives, disease-associated mutations pre-
dicted as neutral.
Accuracy accounts for the fraction of mutations cor-
rectly predicted in function of the total number of
mutations.
Accuracy
TP FN
TP TN FP FN


 
()
()
Recall, also referred to as sensitivity by other authors,
accounts for the proportion of correctly predicted dis-
ease-associated mutations in function of all the disease-
associated mutations in the dataset.
Recall
TP
TP FN


()
()
Precision accounts for the proportion of correctly pre-
dicted disease-associated mutations with respect to all
the predicted disease-associated mutations.
Precision
TP
TP FP


()
()
The F-score is a measure of the accuracy of the classi-
fication. It considers both the precision and the recall in
a single representative score for evaluation purposes.
Fs c o r e
ecision call


2
11
Pr Re
The Matthews Correlation Coefficient (MCC) was cal-
culated according to the following formula:
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TP TN FP FN
TP FN TP FP TN FP TN FN

 

() ()
() ( ) () ( )
 
Classification feature: membership to a kinase group
In order to cluster the kinases according to the groups
they belong to, two different classification schemes were
used. The KinBase resource [30] constitutes the currently
accepted classification scheme of eukaryotic protein
kinases. According to KinBase, kinases are categorized as
‘conventional’ protein kinases (ePKs) or ‘atypical’ protein
kinases (aPKs). The ePKs form the largest group and they
have been subdivided into 8 groups according to
sequence similarity, the presence of accessory domains
and by considering different modes of regulation. The
eight ePK groups defined in KinBase correspond to: the
AGC group (including cyclic-nucleotide and calcium-
phospholipid-dependent kinases, ribosomal S6-phos-
phorylating kinases, G protein-coupled kinases and close
relatives of these kinases); the CAMKs (calmodulin-regu-
lated kinases); the CK1 group (casein kinase 1 and close
relatives); the CMGC group (including cyclin-dependent
kinases, mitogen-activated protein kinases, CDK-like
kinases and glycogen synthase kinase); the RGC group
(receptor guanylate cyclase kinases); the STE group
(MAPK cascade kinases); the TK (tyrosine kinase) and
the TKL (TK-like), which are a group of serine-threonine
kinases resembling TKs. Another broad miscellaneous
group, called ‘Other’, is also considered for those proteins
that do not fit in any of these predefined categories. By
contrast, UniProt [33] provides a classification scheme
that includes the same groups included in KinBase along
with the additional groups, NEK and STG, making a total
of 11 groups. The vector of features submitted to the
classifier contains a position for each of the groups in the
latter scheme. The values are encoded as 1 for the group
to which the kinase housing the mutation belongs to, and
0 for the rest. A similar approach was followed by Torka-
mani and Schork [19].
Classification feature: Gene Ontology log-odds ratio
The Gene Ontology log-odds ratio (GOLOR) was used to
classify the mutations as pathogenic (disease-associated)
or neutral according to the annotations regarding the
function of the genes in which they exist. To compute
the score, we retrieved all the terms associated to the
kinases in our dataset from the 3 sub-ontologies in Gene
Ontology [31] (Molecular Function, Biological Process,
Cell Component). The ontologies were followed towards
the root of each ontology in order to include all parental
terms in the calculation. Note that ‘part-of’ relationships
were discarded and only ‘is-a’ links were considered. For
each of the kinase genes, the sum of the Gene Ontology
Log Odds Ratio (sumGOLOR) was computed as follows:
sumGOLOR
disease genes with GO
neutral genes with GO
i  log2
%
%
    
     i i 
Where disease-associated kinase genes are those with
at least one reported disease-associated mutation and
neutral kinase genes are those with no reported disease-
associated mutation. In order to resolve undetermined
ratios, frequencies equal to 0 were artificially set to 10
–9.
A similar approach with slight changes in the algorithm
is followed in two other methods: CanPredict [13,44]
and SNPs&GO [18].
Classification feature: PFAM domains
The position of the different domains in the sequence of
the human protein kinome was extracted from the
swisspfam file in PFAM [32]. A binary position in the
vector was created for each of the 117 different domains
in the protein kinase family, where 1 means that the
mutation is in a position that was characterized as part
of that domain, and otherwise it is attributed a value 0.
An additional binary position in the vector, PFAM_any,
was created to record whether the position belongs to at
least one PFAM domain. This is a simplified version of
the implementation by other authors [13,16,19].
Classification feature: amino acid type and change in
hydrophobicity
Each amino acid type was encoded at 20 positions in the
vector, where the wild-type residue is encoded as 1 and
its mutant counterpart is encoded as -1.
The rest of values remain as 0 for classification pur-
poses. An additional position was encoded to represent
the change in the Kyte-Doolittle hydrophobicity index
[45].
Classification feature: UniProt annotation
UniProt [33] provides a detailed description of the resi-
dues for a number of proteins in the database. We con-
sidered 5 different classes of residue annotation to be
relevant:
1. Catalytic site (including residues annotated as SITE,
BINDING, ACT_SITE, METAL and NP_BIND: refer to
the UniProt help pages for a detailed description of the
annotations)
2. Disulfide bond (DISULFID)
3. Post-Translational Modifications (MOD_RES,
SIGNAL)
4. Residues with special interest (MUTAGEN)
5. Transmembrane regions (TRANSMEM).
A binary input corresponding to each of these cate-
gories was added to the classification vector. In addition,
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sponds to a positive match in at least one category from
the catalytic site class, while the other corresponds to a
positive match in at least one of the categories described
above. A similar approach was followed previously
[10,14,16,38].
Classification feature: phosphorylation sites
PhosphoELM [41] is a database of eukaryotic phosphory-
lation sites. This resource includes manually curated
information derived from the literature, as well as high-
throughput analyses for 1,232 phosphorylation sites in
287 human kinases present in our dataset. Since out of
the 20 potential residues only 3 can be phosphorylated
(Ser, Tyr, Thr), this feature was encoded for the classifier
according to 3 different states: 1 represents a reported
residue amenable for phosphorylation, 0 if the residue is
a Ser, Thr or Tyr that is not phosphorylated, and -1 for
the remaining residues.
Classification feature: catalytic sites
FireDB [34] is a database of known functionally relevant
residues. It includes both biologically relevant data filtered
from the close atomic contacts in 3D crystal structures
and manually annotated catalytic residues. The presence
of a mutation in the catalytic site of a protein was encoded
in the classifier as a binary input, whereby 1 means that
the mutation is part of the catalytic site, 0 otherwise.
Classification feature: evolutionary information
In order to capture the similarity between closely related
proteins and thereby identify potentially deleterious
changes, we included the SIFT score in our feature vector
[7]. This method relies on the normalized probabilities for
all possible residue substitutions at each position of a mul-
tiple sequence alignment of homologous proteins. The
score can be easily translated into a binary output where
values <0.05 are considered deleterious. Consequently,
both the binary and the continuous versions of the score
were computed in order to provide more discriminating
results. Additionally, the number of sequences in the
alignment at the position of interest was also considered.
Since it was introduced in 2001, this method has been suc-
cessfully incorporated in several predictors of pathogeni-
city [13,14,16,19].
Classification feature: specificity determining positions
Those positions occupied by conserved residues within
groups of proteins in a family sharing a common general
specificity that differs between groups can be used as a
proxy for the regions accounting for subfamily specificity.
SDPs, also referred as tree-determinants on occasion, were
calculated using a simplified version of the in-house S3Det
predictor [35]. In our implementation, the f-score
associated to the wild-type and mutant residues in the
classification of the subfamilies calculated from the
sequences in the PFAM alignments was encoded in the
classification vector. An additional third position repre-
sented the difference between these two scores. This dif-
ference represents the change (increase or decrease) in
agreement with the subfamily introduced by the mutation.
Conclusions
Our choice of features and datasets makes the method
especially relevant in the context of kinase mutations
and their intrinsic role in cancer biology. In our particu-
lar case, the membership to a particular kinase group or
the occurrence of the mutations at the catalytic protein
kinase domain arise as important features that are
unique to the protein kinase superfamily. This is in full
agreement with previous observations [19]. The family-
specific character of the KinMut classifier allowed us to
introduce features that are unique to the protein family
of interest and that retain valuable information about
the pathogenicity of the mutation.
Additional material
Additional file 1: Supplementary figure 1.png Grid optimization of
the predictive power of the classifier (all groups): F-score. We
exhaustively tested the two most critical parameters of the SVM’s radial
basis kernel: soft-margin (C) and radius (g). The average f-score across the
entire set of k-folds was chosen as a scoring function for the
optimization. The optimal values used for the analyses were C = 3 and g
=6·1 0
–4 when all groups in the kinase superfamily were considered.
Additional file 2: Supplementary figure 2.png Grid optimization of
the predictive power of the classifier (all groups): AUC. We exhaustively
tested the two most critical parameters of the SVM’s radial basis kernel:
soft-margin (C) and radius (g). The average area under the curve (AUC)
across the entire set of k-folds was chosen as a scoring function for the
optimization. The optimal values correspond to C = 2 and g =6·1 0
–4.
Additional file 3: Supplementary figure 3.png Grid optimization of
the predictive power of the classifier (populated groups): F-score. Grid
optimization of the predictive power of the classifier when only the
groups with a reasonable number of reported disease-associated
mutations are considered. We exhaustively tested soft-margin (C) and g.
The average f-score across the entire set of k-folds was chosen as the
scoring function for the optimization. The optimal values used during
the analyses were C = 8 and g =1 0
–4.
Additional file 4: Supplementary tables.pdf Supplementary Table 1:
Ranking of the features according to their contribution to classification.
Supplementary Table 2: Most representative GO terms to classify kinase
genes as neutral. Supplementary Table 3: Most representative GO terms
to classify kinase genes as disease-associated.
Additional file 5: Supplementary figure 5.png Benchmark of the
classifiers with a common kinase dataset. Evaluation of the prediction
capabilities of the four genome-wide classifiers (SNPs&GO,
MutationAssessor, SIFT and SNAP) in comparison to KinMut. All predictors
were evaluated with the same kinase dataset. Predictions from SNP&GO
and MutationAssessor were obtained through their respective online
servers while SIFT and SNAP predictions were retrieved from SNPdbe
[42]. The dashed line represents the theoretical random predictor.
Additional file 6: Variants.disease.txt Dataset of disease-associated
mutations used to train and to evaluate the predictor.
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used in to train and to evaluate the predictor.
Acknowledgements
The authors thank the members of the Structural Biology and Biocomputing
Programme (CNIO), especially A. Rausell, D. Juan, I. Ezkurdia and T. Pons, for
interesting discussion and comments on this manuscript. This research was
supported by OpenPhacts European project (115191-2) and Spanish Ministry
of Science and Innovation project BIO2007-6685.
This article has been published as part of BMC Genomics Volume 13
Supplement 4, 2012: SNP-SIG 2011: Identification and annotation of SNPs in
the context of structure, function and disease. The full contents of the
supplement are available online at http://www.biomedcentral.com/
bmcgenomics/supplements/13/S4.
Authors’ contributions
AV and JMGI designed the experiment. AP implemented the classifier. JMGI
and AP trained and evaluated the classifier. JMGI benchmarked the classifier
against the other methods. MV and JMGI designed and developed the web
server. JMGI and AV wrote the paper. All the authors read and approved this
manuscript.
Competing interests
The authors declare that they have no competing interests.
Published: 18 June 2012
References
1. Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D,
Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P,
Markowitz SD, Willis J, Dawson D, Willson JKV, Gazdar AF, Hartigan J, Wu L,
Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B,
Kinzler KW, Velculescu VE: The consensus coding sequences of human
breast and colorectal cancers. Science 2006, 314(5797):268-74.
2. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, Shen D,
Boca SM, Barber TD, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V,
Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z,
Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JKV, Sukumar S, Polyak K,
Park BH, Pethiyagoda CL, Pant PVK, Ballinger DG, Sparks AB, Hartigan J,
Smith DR, Suh E, Papadopoulos N, Buckhaults P, Markowitz SD,
Parmigiani G, Kinzler KW, Velculescu VE, Vogelstein B: The genomic
landscapes of human breast and colorectal cancers. Science 2007,
318(5853):1108-13.
3. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G,
Davies H, Teague J, Butler A, Stevens C, Edkins S, O’Meara S, Vastrik I,
Schmidt EE, Avis T, Barthorpe S, Bhamra G, Buck G, Choudhury B,
Clements J, Cole J, Dicks E, Forbes S, Gray K, Halliday K, Harrison R, Hills K,
Hinton J, Jenkinson A, Jones D, Menzies A, Mironenko T, Perry J, Raine K,
Richardson D, Shepherd R, Small A, Tofts C, Varian J, Webb T, West S,
Widaa S, Yates A, Cahill DP, Louis DN, Goldstraw P, Nicholson AG,
Brasseur F, Looijenga L, Weber BL, Chiew YE, DeFazio A, Greaves MF,
Green AR, Campbell P, Birney E, Easton DF, Chenevix-Trench G, Tan MH,
Khoo SK, Teh BT, Yuen ST, Leung SY, Wooster R, Futreal PA, Stratton MR:
Patterns of somatic mutation in human cancer genomes. Nature 2007,
446(7132):153-8.
4. Baudot A, Real F, Izarzugaza J, Valencia A: From cancer genomes to cancer
models: bridging the gaps. EMBO Rep 2009.
5. Karchin R: Next generation tools for the annotation of human SNPs. Brief
Bioinformatics 2009, 10:35-52.
6. Cline M, Karchin R: Using bioinformatics to predict the functional impact
of SNVs. Bioinformatics 2010.
7. Ng PC, Henikoff S: Predicting deleterious amino acid substitutions.
Genome Res 2001, 11(5):863-74.
8. Clifford RJ, Edmonson MN, Nguyen C, Buetow KH: Large-scale analysis of
non-synonymous coding region single nucleotide polymorphisms.
Bioinformatics 2004, 20(7):1006-14.
9. Reva B, Antipin Y, Sander C: Predicting the functional impact of protein
mutations: application to cancer genomics. Nucleic Acids Res 2011.
10. Ramensky V, Bork P, Sunyaev S: Human non-synonymous SNPs: server
and survey. Nucleic Acids Res 2002, 30(17):3894-900.
11. Wang Z, Moult J: SNPs, protein structure, and disease. Hum Mutat 2001,
17(4):263-70.
12. Krishnan VG, Westhead DR: A comparative study of machine-learning
methods to predict the effects of single nucleotide polymorphisms on
protein function. Bioinformatics 2003, 19(17):2199-209.
13. Kaminker JS, Zhang Y, Waugh A, Haverty PM, Peters B, Sebisanovic D,
Stinson J, Forrest WF, Bazan JF, Seshagiri S, Zhang Z: Distinguishing
cancer-associated missense mutations from common polymorphisms.
Cancer Res 2007, 67(2):465-73.
14. Wainreb G, Ashkenazy H, Bromberg Y, Starovolsky-Shitrit A, Haliloglu T,
Ruppin E, Avraham KB, Rost B, Ben-Tal N: MuD: an interactive web server
for the prediction of non-neutral substitutions using protein structural
data. Nucleic Acids Res 2010, 38(Suppl):W523-8.
15. Ferrer-Costa C, Orozco M, de la Cruz X: Characterization of disease-
associated single amino acid polymorphisms in terms of sequence and
structure properties. J Mol Biol 2002, 315(4):771-86.
16. Bromberg Y, Rost B: SNAP: predict effect of non-synonymous
polymorphisms on function. Nucleic Acids Res 2007, 35(11):3823-35.
17. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P,
Kondrashov AS, Sunyaev SR: A method and server for predicting
damaging missense mutations. Nat Methods 2010, 7(4):248-9.
18. Calabrese R, Capriotti E, Fariselli P, Martelli PL, Casadio R: Functional
annotations improve the predictive score of human disease-related
mutations in proteins. Hum Mutat 2009, 30(8):1237-44.
19. Torkamani A, Schork NJ: Accurate prediction of deleterious protein kinase
polymorphisms. Bioinformatics 2007, 23(21):2918-25.
20. Yue P, Li Z, Moult J: Loss of protein structure stability as a major
causative factor in monogenic disease. J Mol Biol 2005, 353(2):459-73.
21. Karchin R, Diekhans M, Kelly L, Thomas DJ, Pieper U, Eswar N, Haussler D,
Sali A: LS-SNP: large-scale annotation of coding non-synonymous SNPs
based on multiple information sources. Bioinformatics 2005,
21(12):2814-20.
22. González-Pérez A, López-Bigas N: Improving the assessment of the
outcome of nonsynonymous SNVs with a consensus deleteriousness
score, Condel. Am J Hum Genet 2011, 88(4):440-9.
23. Izarzugaza JMG, Krallinger M, Rodriguez-Penagos C, Valencia A: Extraction
of human kinase mutations from literature, databases and genotyping
studies. BMC Bioinformatics 2009, 10(Suppl 8):S1.
24. Hurst J, McMillan L, Porter C, Allen J, Fakorede A, Martin A: The SAAPdb
web resource: A large-scale structural analysis of mutant proteins. Hum
Mutat 2009.
25. Lahiry P, Torkamani A, Schork NJ, Hegele RA: Kinase mutations in human
disease: interpreting genotype-phenotype relationships. Nat Rev Genet
2010, 11:60-74.
26. Greenman C, Wooster R, Futreal PA, Stratton MR, Easton DF: Statistical
analysis of pathogenicity of somatic mutations in cancer. Genetics 2006,
173(4):2187-98.
27. Stratton MR, Campbell PJ, Futreal PA: The cancer genome. Nature 2009,
458(7239):719-24.
28. Izarzugaza JMG, McMillan LEM, Baresic A, Orengo CA, Martin ACR,
Valencia A: Characterization of pathogenic germline mutations in human
Protein Kinases. BMC Bioinformatics 2011, 12(Suppl 4).
29. Izarzugaza J, Redfern O, Orengo C, Valencia A: Cancer-associated
mutations are preferentially distributed in protein kinase functional sites.
Proteins 2009.
30. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S: The protein
kinase complement of the human genome. Science 2002,
298(5600):1912-34.
31. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP,
Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A,
Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G: Gene
ontology: tool for the unification of biology. The Gene Ontology
Consortium. Nat Genet 2000, 25:25-9.
32. Finn RD, Mistry J, Tate J, Coggill P, Heger A, Pollington JE, Gavin OL,
Gunasekaran P, Ceric G, Forslund K, Holm L, Sonnhammer ELL, Eddy SR,
Bateman A: The Pfam protein families database. Nucleic Acids Res 2010,
38(Database issue):D211-22.
33. Bairoch A, Boeckmann B, Ferro S, Gasteiger E: SwissProt: juggling between
evolution and stability. Brief Bioinformatics 2004, 5:39-55.
Izarzugaza et al. BMC Genomics 2012, 13(Suppl 4):S3
http://www.biomedcentral.com/1471-2164/13/S4/S3
Page 10 of 1134. López G, Valencia A, Tress ML: FireDB–a database of functionally
important residues from proteins of known structure. Nucleic Acids Res
2007, 35(Database issue):D219-23.
35. Rausell A, Juan D, Pazos F, Valencia A: Protein interactions and ligand
binding: from protein subfamilies to functional specificity. Proc Natl Acad
Sci USA 2010, 107(5):1995-2000.
36. Care MA, Needham CJ, Bulpitt AJ, Westhead DR: Deleterious SNP
prediction: be mindful of your training data! Bioinformatics 2007,
23(6):664-72.
37. Yue P, Melamud E, Moult J: SNPs3D: candidate gene and SNP selection
for association studies. BMC Bioinformatics 2006, 7:166.
38. Ye ZQ, Zhao SQ, Gao G, Liu XQ, Langlois RE, Lu H, Wei L: Finding new
structural and sequence attributes to predict possible disease
association of single amino acid polymorphism (SAP). Bioinformatics 2007,
23(12):1444-50.
39. Guyon I, Weston J, Barnhill S, Vapnik V: Gene Selection for Cancer
Classification using Support Vector Machines. Support Vector Machines
2002, 46:389-422.
40. Rakotomamonjy A: Variable selection using SVM-based criteria. JMLR
2003, 3:1357-70.
41. Diella F, Gould CM, Chica C, Via A, Gibson TJ: Phospho.ELM: a database of
phosphorylation sites-update 2008. Nucleic Acids Res 2008, 36(Database
issue):D240-4.
42. Schaefer C, Meier A, Rost B, Bromberg Y: SNPdbe: constructing an nsSNP
functional impacts database. Bioinformatics 2012, 28(4):601-2.
43. Torkamani A, Kannan N, Taylor SS, Schork NJ: Congenital disease SNPs
target lineage specific structural elements in protein kinases. Proc Natl
Acad Sci USA 2008, 105(26):9011-6.
44. Kaminker JS, Zhang Y, Watanabe C, Zhang Z: CanPredict: a computational
tool for predicting cancer-associated missense mutations. Nucleic Acids
Res 2007, 35(Web Server issue):W595-8.
45. Kyte J, Doolittle RF: A simple method for displaying the hydropathic
character of a protein. J Mol Biol 1982, 157:105-32.
doi:10.1186/1471-2164-13-S4-S3
Cite this article as: Izarzugaza et al.: Prioritization of pathogenic
mutations in the protein kinase superfamily. BMC Genomics 2012 13
(Suppl 4):S3.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Izarzugaza et al. BMC Genomics 2012, 13(Suppl 4):S3
http://www.biomedcentral.com/1471-2164/13/S4/S3
Page 11 of 11